PRESS RELEASE Paris, 25th February 2026 Half-year results at the end of December 2025 Quality offering driving revenue growth, with continued efficiency supporting operational profitability Public funding to mitigate cost inflation still a challenge Group Revenue up 3.3% to €2.6bn (+2.3% LFL) from (i) a recognized quality offering driving volumes in France and (ii) strong fundamentals in the Nordics, with positive price indexation and favourable currency effects.Group EBITDA stable at €285m (11.0% margin) ...

Core Viewpoint - Tecan Group will present its full-year 2025 financial results and provide a Capital Markets Update on March 16, 2026, at an Analyst and Media Conference in Zurich [1][2]. Group 1: Event Details - The Analyst and Media Conference will take place at Metropol Zurich on March 16, 2026, at 2:00 pm CET [1]. - The event will be audio-webcast with synchronized presentation slides, and in-person attendance requires prior registration due to limited capacity [2]. - A replay of the webcast will be available on Tecan's website for 12 months following the presentation [3]. Group 2: Company Overview - Tecan is a pioneer in laboratory automation and a global leader in developing and manufacturing OEM instruments, components, and medical devices [4]. - Founded in Switzerland in 1980, Tecan employs over 3,000 people and has manufacturing, research, and development sites in Europe, North America, and Asia [4]. - The company maintains a sales and service network in over 70 countries and is listed on the SIX Swiss Exchange under the ticker TECN [4].

SPDR S&P Biotech ETF (XBI US) – Investment PropositionSPDR S&P Biotech ETF (XBI) provides targeted exposure to U.S. biotechnology companies across the market-cap spectrum, emphasizing a diversified, balanced approach that reduces reliance on a few mega-caps. The strategy seeks to capture innovation-led growth by spreading risk across firms engaged in drug discovery, clinical development, and specialized therapeutics, limiting single-name and sub-industry concentration. Portfolio returns are largely driven b ...

Core Viewpoint - The presentation emphasizes the importance of the healthcare industry and the comprehensive portfolio of Fresenius SE, which includes hospitals, pharmaceuticals, and medical technology, highlighting their commitment to healthcare innovation and services [2][3]. Group 1: Company Overview - Fresenius SE operates across a wide spectrum of healthcare services, including hospitals, pharmaceuticals, and medical technology, showcasing a holistic approach to health care [2]. - The company positions itself as a leader in the healthcare sector, with a focus on innovative products and services that cater to various health needs [2]. Group 2: Industry Context - The timing of the conference is noted as particularly significant due to the ongoing changes in the healthcare landscape, indicating a dynamic environment that necessitates collaboration and discussion among industry leaders [3].

Core Insights - Acentra Health has been recognized among Modern Healthcare's 2025 Best in Business in the Healthcare IT category, highlighting its role in driving innovation and excellence in the healthcare industry [1][3] Company Achievements - Acentra Health's Medicaid Enterprise System (MES) solution was the first to receive the Centers for Medicare & Medicaid's Streamlined Claims Module Certification and is highly ranked in NASPO ValuePoint™ categories [2] - The company has successfully reduced hospitalizations, emergency department visits, and assessment turnaround times through its care management programs [2] - Acentra Health has achieved a 12% reduction in Medicaid costs and a 20% increase in primary care use in Oregon, supporting nearly 3,000 individuals through its housing and rent assistance program [7] Industry Impact - Acentra Health serves beneficiaries in all 50 states, improving access to healthcare for over 170 million people [3] - The company is recognized for its innovative approaches that redefine care delivery and operations, contributing to the overall progress in the healthcare ecosystem [3]

Financial Sector Insights - Major banks including JPMorgan, Bank of America, and Goldman Sachs are reporting earnings this week, providing insights into consumer spending, business loan demand, and credit quality trends [1][2] - Key metrics such as net interest margins, loan loss provisions, and deposit dynamics will be critical for assessing bank conditions [1] - Investment banking revenues will shed light on M&A activity and capital markets health, while wealth management results will reflect retail investor sentiment [1] Economic Data Releases - The December CPI report is anticipated to be a significant economic release, indicating inflation trends as 2025 concludes [3] - Both headline and core CPI readings will be closely monitored for signs of inflation reacceleration, which could impact Federal Reserve policy [3] - Retail sales data will provide context on consumer demand strength, influencing pricing power and market sentiment [3] Semiconductor Sector Update - Taiwan Semiconductor's earnings will be crucial for understanding global semiconductor demand, particularly in AI and other end markets [4] - Insights on advanced node utilization and capital expenditure plans will be vital for assessing the sustainability of AI-driven chip demand [4] - TSM's commentary on competition from Samsung and Intel will provide context on industry dynamics and future investment expectations [4] Retail Sector Analysis - The NRF 2026 and ICR conferences will offer significant retailer preannouncements and guidance updates, impacting consumer discretionary sector sentiment [6] - November retail sales data will provide hard evidence of holiday shopping performance, with comparisons to conference commentary being critical for assessing retailer optimism [6] - Existing home sales data will further contextualize consumer behavior in the residential real estate market [6] Healthcare Sector Developments - The JPMorgan Healthcare Conference will gather key players in the pharmaceutical and biotech industries, generating significant news flow [7] - Updates on pipeline developments and regulatory approvals from major drugmakers could substantially influence stock movements [7] - The conference will highlight critical themes such as drug pricing pressures and innovations in oncology and gene therapy [7]

Core Viewpoint - Johnson & Johnson has entered a voluntary agreement with the Trump Administration aimed at improving access to medicines and reducing costs for American patients, while also receiving an exemption from tariffs for its pharmaceutical products [1][2]. Group 1: Investment and Manufacturing - The company is committed to a $55 billion investment in U.S. manufacturing, research and development, and technology by early 2029, with billions already initiated in the last 10 months [3][4]. - As part of this investment, Johnson & Johnson is establishing two new U.S. manufacturing facilities, including a cell therapy site in Pennsylvania and a drug product facility in North Carolina [4]. - A $2 billion biologics manufacturing facility is under construction in Wilson, North Carolina, expected to create approximately 5,000 skilled jobs [5]. - The company has secured a new 160,000+ square foot biopharmaceutical manufacturing site in Holly Springs, North Carolina, with a $2 billion commitment over the next 10 years, creating around 120 new jobs [6]. Group 2: Access and Pricing - Johnson & Johnson is participating in TrumpRx.gov, a platform that allows American patients to purchase medicines at significantly discounted rates [8]. - The company aims to enable American patients to access medicines at prices comparable to those in other developed countries and provide Medicaid program access at similar pricing [8].

Core Insights - Astellas Pharma Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its strategic focuses and progress in delivering long-term impact for patients, partners, and shareholders [1][2] Company Strategy and Leadership - President and CEO Naoki Okamura will discuss Astellas' key growth drivers and commitment to disciplined execution, while Chief Research & Development Officer Tadaaki Taniguchi will emphasize advancements in transformative scientific breakthroughs for diseases with high unmet medical needs [2][3] - The company aims to turn innovative science into meaningful value for patients and drive sustainable growth, using the conference as a platform to engage with the global investment and healthcare community [3] Event Details - The presentation will take place on January 12, 2026, at 3:00 p.m. PT at the Westin St. Francis, San Francisco, with materials and a live webcast available on Astellas' Investor Relations page [8] Industry Engagement - Astellas is also a distinguished sponsor of the Biotech Showcase, further enhancing its visibility in the global life sciences community, with Chief Strategy Officer Adam Pearson participating in discussions on partnering trends that advance emerging technologies and drug development innovation [4]

近日，深圳市人大常委会通过《关于突出临床重点专科建设进一步提升医疗治疗水平的决定》，明 确"十五五"时期将推进100个临床重点专科建设，建成30个重点疾病专科医疗中心。中山大学附属第七 医院二期的启用与运营，正是对这一战略部署的率先响应和实体支撑。 深化医教协同，培育本土高层次医学人才队伍，提升临床教学的质量和水平，建立"国家级名医—中青 年骨干—青年医师"的传帮带体系。 科研与转化方面构建"基础研究—临床研究—成果转化及产业化—临床应用"产学研创新体系，培育本土 生物医药产业创新人才，建设高层次服务平台、完善服务链条，丰富生物医药与健康集群。 借助30分钟直达机场、31分钟高铁连通香港的便利，以及智慧化手段，医院将持续优化导诊、停车等配 套服务，为更多人群提供接轨国际的医疗服务。 二期项目创新采用多中心、组团式布局，让患者在专病中心内即可完成挂号、看诊、检查、住院等全流 程，医院不再是一个整体迷宫，而是由多个按疾病系统划分的"小医院"（中心）组成。如患者看心血管 疾病，可进入"心血管中心"，在该中心里，门诊、诊室、专属的检查设备（如心脏彩超）、住院病房， 甚至手术室，都集中在同一栋楼或相邻楼层。患者和家属无 ...

Core Insights - The US healthcare industry is experiencing new growth opportunities due to innovations such as GLP-1 agonists and gene therapies, following several years of low returns and volatility [1] Group 1: Industry Overview - The healthcare sector has faced challenges in the past three years, characterized by significant volatility and low returns [1] - Recent innovations are providing tailwinds that could enhance the sector's performance moving forward [1]